The expanding role of the community oncology pharmacist in modern cancer care

Drawing on insights from several recent oncology-focused congresses, Tom Rotolo, Vice President of Medical Strategy at MEDiSTRAVA, an Inizio Medical company, explores how the role of the community oncology pharmacist is rapidly evolving. A primary theme has emerged: the community oncology pharmacist is no longer a supporting player—they are becoming a central coordinator of care. As innovation accelerates and treatment complexity grows, pharmacists are uniquely positioned to connect clinical, operational, and technological elements across the patient journey.  

From dispensing to directing care pathways: Sessions have highlighted how pharmacists are increasingly coordinating treatment decisions in real time. Data and experiences have emphasized their role in interpreting genomic data, aligning therapies with evidence-based pathways, and ensuring appropriate sequencing of treatments. This evolution positions pharmacists as key navigators of increasingly complex regimens, especially as community practices expand access to advanced therapies like bispecific antibodies and cellular treatments in outpatient settings.  

Bridging fragmented provider ecosystems: Another clear shift is the pharmacist’s role as a connector across traditionally siloed providers. In community settings, where patients often receive care close to home but across multiple providers, pharmacists are emerging as the consistent touchpoint. They facilitate communication between physicians, nurses, specialty pharmacies, and payers, helping reduce delays, prevent duplicative therapies, and ensure continuity of care. 

Driving formulary and value-based decisions: As drug costs rise and reimbursement models evolve, pharmacists are also playing a larger role in formulary management and value assessment. Conference discussions around policy, sustainability, and payer engagement reflect how pharmacists contribute to decisions on therapy adoption, formulary inclusion, biosimilars, and cost-effective regimens. Their clinical expertise, combined with real-world insight into patient adherence and toxicity management, allows them to influence formulary strategies that balance innovation with affordability—an increasingly critical need in community oncology. 

Powering Electronic Health/Medical Record (EHR/EMR) integration and longitudinal monitoring: Perhaps the most transformative shift is the pharmacist’s role in leveraging digital tools. With sessions highlighting AI, data transparency, and operational innovation, pharmacists are helping embed treatment pathways, safety checks, and adherence monitoring directly into EHR/EMR systems. In practice, this means pharmacists are designing and managing “flagging systems” that track lab values, adverse events, and therapy milestones to facilitate awareness across the continuum of care. These systems enable proactive interventions, whether adjusting doses, addressing toxicities, or identifying non-adherence before it impacts outcomes. 

A new model for community oncology care: The key takeaways are clear: the community oncology pharmacist is evolving into a clinical integrator—coordinating treatments, connecting stakeholders, guiding formulary strategy, and operationalizing data-driven care. Pharmacists are no longer working at the margins of care; they are helping to design and drive cooperative strategies to improve patient outcomes. 

Interested in more real-world oncology insights? Visit our Real-World iNSIGHTS page here.